ESMO Advanced Course on Endocrine Sensitivity in HR+/HER2− Metastatic Breast Cancer 2026
The ESMO Advanced Course on Defining Endocrine Sensitivity & Optimising Treatment Strategies in HR+/HER2− mBC Patients 2026, organized by the European Society for Medical Oncology (ESMO), will take place on November 25, 2026, in Barcelona, Spain. The course will focus on the increasingly complex management of hormone receptor-positive, HER2-negative metastatic breast cancer, particularly how clinicians […]